Your browser doesn't support javascript.
loading
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
Blauvelt, Andrew; Eyerich, Kilian; Irvine, Alan D; de Bruin-Weller, Marjolein; Kwatra, Shawn G; Gooderham, Melinda; Kim, Brian; Calimlim, Brian M; Lee, Wan-Ju; Raymundo, Eliza M; Liu, Yingyi; Ofori, Sarah; Platt, Andrew M; Silverberg, Jonathan I.
Afiliación
  • Blauvelt A; Blauvelt Consulting LLC, Lake Oswego, OR, USA. blauveltconsults@gmail.com.
  • Eyerich K; Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany.
  • Irvine AD; Clinical Medicine, Trinity College Dublin and Wellcome-HRB Clinical Research Facility, St James's Hospital, Dublin, Ireland.
  • de Bruin-Weller M; National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Kwatra SG; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Gooderham M; SKiN Centre for Dermatology, Peterborough, ON, Canada.
  • Kim B; Probity Medical Research, Peterborough, ON, Canada.
  • Calimlim BM; Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Lee WJ; Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Raymundo EM; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Liu Y; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ofori S; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Platt AM; AbbVie Inc., North Chicago, IL, USA.
  • Silverberg JI; AbbVie Inc., North Chicago, IL, USA.
Dermatol Ther (Heidelb) ; 14(9): 2621-2630, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39110139
ABSTRACT

INTRODUCTION:

Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients' quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment versus placebo or dupilumab among patients with moderate-to-severe AD.

METHODS:

This analysis consisted of a post hoc analysis of Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 were replicate, randomized, double-blind, placebo-controlled phase 3 studies with patients randomized (111) to once-daily oral upadacitinib 15 mg, upadacitinib 30 mg, or placebo for 16 weeks. Heads Up was a head-to-head, randomized, double-blind, double-dummy, phase 3b study with patients randomized (11) to upadacitinib 30 mg or subcutaneous dupilumab 300 mg for 24 weeks. Skin clearance was assessed with the Eczema Area and Severity Index (EASI) at baseline, weeks 1, 2, and 4, and every 4 weeks thereafter. Itch was assessed using the Worst Pruritus Numerical Rating Scale (WP-NRS) daily over 16 weeks and every 2 weeks thereafter to week 24 in Heads Up.

RESULTS:

This analysis included 1683 patients in Measure Up 1 and 2 and 673 patients in Heads Up. Through 16 weeks in Measure Up 1 and 2, patients receiving upadacitinib spent 9.8-13.4 times as many days with an EASI 90 response and 7.0-10.3 times as many days with a WP-NRS 0/1 response versus placebo. In Heads Up, patients receiving upadacitinib spent 2.0 and 1.7 times as many days through 16 and 24 weeks, respectively, with an EASI 90 response versus dupilumab. Through 16 and 24 weeks, patients receiving upadacitinib spent 3.0 and 2.6 times as many days, respectively, with a WP-NRS 0/1 response versus dupilumab.

CONCLUSIONS:

Patients with moderate-to-severe AD spent more time with clear/almost clear skin and no/minimal itch with upadacitinib versus placebo or dupilumab. TRIAL REGISTRATION ClinicalTrials.gov identifier, Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), Heads Up (NCT03738397).
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza